...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Chinese-German Journal of Clinical Oncology >Preparation and Bioactivity Assay of CD3AK Cell from Umbilical Cord Blood: ― Clinic Report of 10 Tumor Cases
【24h】

Preparation and Bioactivity Assay of CD3AK Cell from Umbilical Cord Blood: ― Clinic Report of 10 Tumor Cases

机译：脐血CD3AK细胞的制备及生物活性测定：― 10例肿瘤的临床报道

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To study the anti-tumor effect of CD3AK cell prepared from umbilical blood, to explore the short-term curative effect on tumor cases and seek better immune index for biotherapy. Methods IL-2 and IL-2 + CD3Ab were used to induce LAK cells and CD3AK cells isolated from umbilical blood mononuclear cells (UB-MC). The expanding number and bioactivity of LAK cells and CD3AK cells were examined at different time points after culture, the NK activity of peripheral blood mononuclear cells (PBMC) of 10 cases of malignant tumor were determined before and after CD3AK cell adopting immune therapy as well. Results The number and bioactivity (NK killing K562 cell) of LAK and CD3AK cells reached their peaks on 11 th day. The number of LAK and CD3AK cells were 18 folds and 24 folds of that before culture; The NK activities of LAK and CD3AK against K562 were 2.6 folds and 3.2 folds of those before culture respectively. The NK activity for killing K562 cells of malignant tumor patient's PBMC was increased from 63% - 81% by CD3AK cell transfusing, rising mean 28%. Conclusion (1) The UBMC is a potential and better source of predecessor for LAK and CD3AK; (2) The NK activity of LAK and CD3AK cells from UBMC reached their peaks at 11 th day after culture, and the NK activity of CD3AK cells is much greater than that of LAK cells; (3) The NK activity of malignant tumor patient's PBMC can be obviously elevated by transfusing CD3AK cell; (4) The test of NK activity of PBMC of malignant tumor patient may become an objective immune index for tumor biotherapy.
机译：目的研究脐血制备的CD3AK细胞的抗肿瘤作用，探讨其对肿瘤病例的短期治疗效果，寻求更好的生物治疗免疫指标。方法用IL-2和IL-2 + CD3Ab诱导从脐血单核细胞（UB-MC）分离的LAK细胞和CD3AK细胞。在培养后的不同时间点观察LAK和CD3AK细胞的扩增数量和生物活性，并在免疫治疗前后分别测定10例恶性肿瘤的外周血单个核细胞（PBMC）的NK活性。结果LAK和CD3AK细胞数量和生物活性（NK杀伤K562细胞）在第11天达到高峰。 LAK和CD3AK细胞的数量分别是培养前的18倍和24倍。 LAK和CD3AK对K562的NK活性分别是培养前的2.6倍和3.2倍。通过CD3AK细胞输注，杀死恶性肿瘤患者PBMC K562细胞的NK活性从63％-81％增加，平均提高28％。结论（1）UBMC是LAK和CD3AK的潜在和更好的前身来源； （2）UBMC培养的LAK和CD3AK细胞的NK活性在培养后第11天达到峰值，CD3AK细胞的NK活性比LAK细胞大。 （3）通过输注CD3AK细胞可明显提高恶性肿瘤患者PBMC的NK活性； （4）检测恶性肿瘤患者PBMC的NK活性可能成为肿瘤生物治疗的客观免疫指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号